United Therapeutics CEO’s 10b5‑1 Moves Signal Confidence in Undervalued Stock and Strong Pipeline

Insider Activity at United Therapeutics Corp. – What the Latest 4 Filing Tells Investors

10b5‑1 Plan in Action

On June 9, 2026, Martine Rothblatt, chairperson and chief executive officer of United Therapeutics Corp., executed a purchase of 9,500 shares of common stock through a pre‑arranged 10b5‑1 plan that was adopted in November of the previous year. The plan permits the exercise of up to 1.73 million options that expire by March 2027, thereby providing a “safe‑haven” for insider trading that is independent of market conditions. The purchase price of $146.03 per share, approximately 20 % below the then‑market price of $553, suggests a strategic decision rather than opportunistic trading. It signals confidence that the stock is undervalued relative to the lock‑in price set by the plan, and aligns with the company’s positive earnings guidance and a pipeline of pulmonary hypertension therapies that remains promising.

Recent Sales Paint a Mixed Picture

In the same week, Rothblatt sold more than 50,000 shares in a series of transactions at progressively higher prices—from $544.69 to $551.35. The timing and volume of these sales, most of which occurred early on June 9, are consistent with a disciplined execution of the 10b5‑1 plan. While the average sale price is above the current market level, the cumulative proceeds indicate a substantial divestment of her direct holdings. This pattern—selling common stock at premium prices while simultaneously purchasing shares at lower levels—reflects a long‑term strategic plan rather than a reaction to short‑term market movements.

What It Means for Investors

Rothblatt’s Transaction Profile

Over the past month, Rothblatt’s trading history shows frequent, small‑to‑medium‑sized trades executed on a daily basis. The majority involve selling common stock at premium prices, with periodic purchases at lower levels. She also sells options in large blocks, as seen with the 9,500‑share option sell on June 9, which likely reflects a planned liquidation of future equity exposure. Her trust holdings account for the bulk of her stake, ensuring that even after the sales, her influence remains largely intact. The overall pattern aligns with a long‑term strategic plan rather than short‑term speculation.

Company‑Wide Insider Activity

Other insiders, such as CFO Edgemond James, have been buying shares (10,000 at $117.76) to support the stock, while other executives have also sold shares at higher prices. This mix of buying and selling is typical in a biotechnology firm with a volatile share price. The fact that no other insider is buying a controlling block suggests that the current ownership structure remains stable.

Bottom Line for Investors

Rothblatt’s 10b5‑1 purchase amid a string of sales is a calculated move that reaffirms her confidence in United Therapeutics’ long‑term prospects. For investors, the trade signals a potential undervaluation at the current price and provides a window to evaluate the company’s pipeline and earnings trajectory. As the market digests the transaction, watch for any shift in sentiment or trading volume, and keep an eye on upcoming clinical milestones that could validate the CEO’s bullish stance.

Transaction Summary (Form 4 – 2026‑06‑09)